To increase the likelihood of identifying useful plasma biomarkers, we focused on the microRNAs that showed the highest degrees of dysregulation in the ALK-positive NSCLC samples (fold-change in comparison to ALK-negative NSCLC) and that were among the most abundant in terms of absolute expression levels. This evidence concerns the gene ALK and non-small cell lung carcinoma.